Feeble awake effects of plasminogen activator inhibitor type-1 in mice

• Published in: Behavioural brain research 2011-07, Vol.220 (2), p.354-357
• Main Authors: Sakakibara, Hiroyuki, Romanowski, Christoph P.N., Jakubcakova, Vladimira, Flachskamm, Cornelia, Shimoi, Kayoko, Kimura, Mayumi
• Format: Article
• Language: English
• Subjects: Analysis of Variance; Animals; Behavioral psychophysiology; Biological and medical sciences; Brain Waves - drug effects; Dose-Response Relationship, Drug; Electroencephalography - methods; Electromyography - methods; Fundamental and applied biological sciences. Psychology; Injections, Intraperitoneal - methods; Male; Mice; Mice, Inbred C57BL; Non-rapid eye movement sleep; Plasminogen Activator Inhibitor 1 - blood; Plasminogen Activator Inhibitor 1 - pharmacology; Plasminogen activator inhibitor-1; Psychology. Psychoanalysis. Psychiatry; Psychology. Psychophysiology; Sleep; Sleep–wake patterns; Stress; Time Factors; Wakefulness; Wakefulness - drug effects
• ISSN: 0166-4328; 1872-7549
• DOI: 10.1016/j.bbr.2011.02.023

► Plasminogen activator inhibitor-type 1 (PAI-1) increases its plasma levels after intraperitoneal injection. ► PAI-1 can promote wakefulness in mice but the effects do not last long. ► Stress-induced PAI-1 may contribute to disturbed sleep in stress-related diseases. ► However, elevated PAI-1 would be rather a marker but not a cause of sleep disorders. Plasminogen activator inhibitor-type 1 (PAI-1) is involved in the fibrinolytic system and shows its increased levels in diseases, e.g., obesity and sleep apnea syndrome. The aim of the study is to investigate whether PAI-1 affects sleep–wake patterns in mice. When recombinant mouse PAI-1 was administered intraperitoneally, only rapid but short increases in time spent awake were observed after 20 or 100 μg/kg, although its plasma concentration was kept high for an hour. The results suggest that PAI-1 may serve its role rather as a marker than an initiator of disturbed sleep.